Skip to main content
Year archive

Marinomed Biotech AG — 2024 filings

All 109 regulatory filings released by Marinomed Biotech AG (MARI) in 2024, sourced directly from the official regulator.

109 Filings
2024 Period
2024 filings (109)
Filing Released Lang
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-12-31 English
EQS-NVR: Marinomed Biotech AG: Release according to Article 135, Section 1 BörseG with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2024-12-31 English
EQS-NVR: Marinomed Biotech AG: Veröffentlichung der Gesamtstimmrechte nach § 135 Abs. 1 BörseG mit dem Ziel der europaweiten Verbreitung
Declaration of Voting Results & Voting Rights Announcements
2024-12-31 German
EQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2024-12-30 English
EQS-PVR: Marinomed Biotech AG: Veröffentlichung gemäß § 135 Abs. 2 BörseG mit dem Ziel der europaweiten Verbreitung
Declaration of Voting Results & Voting Rights Announcements
2024-12-30 German
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-12-30 English
Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
AGM Information
2024-12-20 English
Marinomed Biotech AG: Extraordinary general meeting approves sale of Carragelose division
AGM Information
2024-12-19 English
Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved
Legal Proceedings Report
2024-12-18 English
Marinomed Biotech AG: Requirements for successful completion of the restructuring proceedings achieved
Legal Proceedings Report
2024-12-17 English
Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share
Share Issue/Capital Change
2024-12-06 English
EQS-Adhoc: Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share
Share Issue/Capital Change
2024-12-05 English
EQS-Adhoc: Marinomed Biotech AG beschließt zweite Kapitalerhöhung unter Bezugsrechtsausschluss durch Ausgabe von 83.750 auf Inhaber lautenden Stückaktien zum Ausgabebetrag von EUR 8 je Aktie
Share Issue/Capital Change
2024-12-05 German
Marinomed Biotech AG resolves second capital increase excluding statutory subscription rights by issuing 83,750 no-par value bearer shares at an issue price of EUR 8 per share
Share Issue/Capital Change
2024-12-05 English
Marinomed Biotech AG: Invitation to an Extraordinary General Meeting on Thursday, December 19, 2024, at 9:00 a.m. (Vienna time)
AGM Information
2024-11-29 English
Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank (EIB) signed
Capital/Financing Update
2024-11-28 English
EQS-AGM: Marinomed Biotech AG: Invitation to an Extraordinary General Meeting on Thursday, December 19, 2024, at 9:00 a.m. (Vienna time)
AGM Information
2024-11-28 English
EQS-HV: Marinomed Biotech AG: Einberufung einer außerordentlichen Hauptversammlung für Donnerstag, den 19. Dezember 2024 um 9:00 Uhr (Wiener Zeit)
AGM Information
2024-11-28 German
Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals
M&A Activity
2024-11-27 English
EQS-Adhoc: Marinomed Biotech AG: Binding Term Sheet for the intended issuance of a convertible bond to the European Investment Bank signed
Capital/Financing Update
2024-11-27 English
EQS-Adhoc: Marinomed Biotech AG: Bindendes Term Sheet für beabsichtigte Ausgabe einer Wandelschuldverschreibung an die Europäische Investitionsbank unterzeichnet
Capital/Financing Update
2024-11-27 German
EQS-Adhoc: Marinomed Biotech AG: Publication of a report on the exclusion of subscription rights for a possible second cash capital in-crease of up to 154,053 shares
Report Publication Announcement
2024-11-27 English
EQS-Adhoc: Marinomed Biotech AG: Veröffentlichung eines Berichts zum Bezugsrechtsausschluss für mögliche zweite Barkapitalerhöhung um bis zu 154.053 Stückaktien
Capital/Financing Update
2024-11-27 German
EQS-Adhoc: Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals
M&A Activity
2024-11-26 English
EQS-Adhoc: Marinomed Biotech AG unterzeichnet Vereinbarung über den Verkauf des Carragelose-Geschäfts an das französische Unternehmen Unither Pharmaceuticals
M&A Activity
2024-11-26 German
Marinomed Biotech AG signs agreement for sale of Carragelose business to French Unither Pharmaceuticals
M&A Activity
2024-11-26 English
EQS-Adhoc: Marinomed Biotech AG announces unanimous approval of the restructuring plan by creditors
Legal Proceedings Report
2024-11-14 English
EQS-Adhoc: Marinomed Biotech AG gibt einstimmige Zustimmung der Gläubiger zum Sanierungsplan bekannt
Legal Proceedings Report
2024-11-14 German
Marinomed Biotech AG publishes clinical data for decongestant Carragelose nasal spray in peer-reviewed International Journal of General Medicine
Regulatory Filings
2024-11-12 English
EQS-PVR: Marinomed Biotech AG: Release according to Article 135, Section 2 BörseG with the objective of Europe-wide distribution
Major Shareholding Notification
2024-10-24 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-10-24 German
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-10-24 English
M&A Activity 2024
M&A Activity
2024-10-11 English
M&A Activity 2024
M&A Activity
2024-10-11 German
Marinomed Biotech AG begins contract negotiations for the sale of the Carragelose portfolio
M&A Activity
2024-10-11 English
Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal
Earnings Release FY 2024
2024-10-08 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-30 German
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-30 German
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-30 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-30 German
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-30 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-30 German
Release according to Article 135, Section 1 BorseG with the objective of Europe-wide distribution
Declaration of Voting Results & Voting Rights Announcements
2024-09-30 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-09-26 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-26 German
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-09-26 English
Director's Dealing 2024
Director's Dealing
2024-09-20 English
Director's Dealing 2024
Director's Dealing
2024-09-20 English
Director's Dealing 2024
Director's Dealing
2024-09-20 English
Director's Dealing 2024
Director's Dealing
2024-09-20 German
Director's Dealing 2024
Director's Dealing
2024-09-20 German
Director's Dealing 2024
Director's Dealing
2024-09-20 German
Marinomed Biotech AG: Simon Nebel, buy
Director's Dealing
2024-09-20 English
Capital/Financing Update 2024
Capital/Financing Update
2024-09-18 English
Capital/Financing Update 2024
Capital/Financing Update
2024-09-18 German
Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Capital/Financing Update
2024-09-18 English
Capital/Financing Update 2024
Capital/Financing Update
2024-09-15 English
Share Issue/Capital Change 2024
Share Issue/Capital Change
2024-09-15 German
Marinomed Biotech AG sets price range for potential 10% capital increase and potential second capital increase, in each case excluding statutory subscription rights
Capital/Financing Update
2024-09-15 English
Marinomed Biotech AG: First Carragelose products receive new Medical Device Regulation (MDR) certification
Regulatory Filings
2024-09-11 English
Capital/Financing Update 2024
Capital/Financing Update
2024-09-02 English
Capital/Financing Update 2024
Capital/Financing Update
2024-09-02 German
Marinomed Biotech AG evaluates possible 10% capital increase with exclusion of statutory subscription rights
Capital/Financing Update
2024-09-02 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-08-22 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-08-22 German
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-08-22 English
Marinomed Biotech AG reports preliminary financial figures for the first half of 2024
Earnings Release H1 2024
2024-08-20 English
Legal Proceedings Report 2024
Legal Proceedings Report
2024-08-14 English
Legal Proceedings Report 2024
Legal Proceedings Report
2024-08-14 German
Marinomed Biotech AG: Court opens restructuring proceedings without self-administration
Regulatory Filings
2024-08-14 English
Marinomed Biotech AG aims for financial reorganization by restructuring proceedings without self-administration
Legal Proceedings Report
2024-08-14 English
Regulatory Filings 2024
Regulatory Filings
2024-08-13 English
Legal Proceedings Report 2024
Legal Proceedings Report
2024-08-13 German
Marinomed Biotech AG applies for court restructuring proceedings without self-administration
Regulatory Filings
2024-08-13 English
Marinomed Biotech AG secures licensure with leading Consumer Health Care player for the distribution of Carragelose products in Europe
Regulatory Filings
2024-06-14 English
AGM Information 2024
AGM Information
2024-05-23 English
AGM Information 2024
AGM Information
2024-05-23 German
Marinomed Biotech AG: Invitation to the 7th Annual General Meeting on Thursday, June 20, 2024, at 13:00 (Vienna time)
AGM Information
2024-05-23 English
Marinomed Biotech AG announces results for the first quarter of 2024
Earnings Release Q1 2024
2024-05-22 English
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2024-04-30 German
Annual Report (ESEF) 2022
Annual Report (ESEF) FY 2022
2024-04-25 German
Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Ache Laboratorios
M&A Activity
2024-04-25 English
Annual Report (ESEF) 2023
Annual Report (ESEF) FY 2023
2024-04-16 German
Annual Report (ESEF) 2023
Annual Report (ESEF) FY 2023
2024-04-16 German
Report Publication Announcement 2024
Report Publication Announcement
2024-04-16 English
Annual Report 2023
Annual Report FY 2023
2024-04-16 German
Annual Report 2023
Annual Report FY 2023
2024-04-16 German
Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets
Earnings Release FY 2023
2024-04-16 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-04-15 English
Major Shareholding Notification 2024
Major Shareholding Notification
2024-04-15 German
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-04-15 English
Marinomed Biotech AG: Launch of new allergen-blocking Carragelose product in Austria and market entry in Mexico
Regulatory Filings
2024-04-11 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-03-31 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-03-31 German
Change of total number of voting rights and capital according to article 135 section 1 BorseG
Declaration of Voting Results & Voting Rights Announcements
2024-03-31 English
Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months
Capital/Financing Update
2024-03-28 English
Marinomed Biotech AG enters new Carragelose distribution partnerships for Gulf region and Eastern Europe
M&A Activity
2024-03-26 English
Marinomed Biotech AG: Lucia Ziegler new Head of Investor & Public Relations
Board/Management Information
2024-03-01 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-02-29 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-02-29 German
Change of total number of voting rights and capital according to article 135 section 1 BorseG
Declaration of Voting Results & Voting Rights Announcements
2024-02-29 English
Marinomed Biotech AG announces preliminary revenue for 2023
Earnings Release FY 2023
2024-02-14 English
Marinomed Biotech AG with important progress for Carragelose in 2024
Regulatory Filings
2024-02-07 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-01-31 English
Declaration of Voting Results & Voting Rights Announcements 2024
Declaration of Voting Results & Voting Rights Announcements
2024-01-31 German